
Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – Equities researchers at HC Wainwright issued their FY2027 EPS estimates for shares of Basilea Pharmaceutica in a research report issued on Friday, November 13th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn $7.60 per share for the year. The consensus estimate for Basilea Pharmaceutica’s current full-year earnings is $8.49 per share.
Basilea Pharmaceutica Stock Performance
Shares of BPMUF stock opened at $84.00 on Monday. The company has a 50 day moving average of $77.42 and a 200-day moving average of $70.11. The company has a debt-to-equity ratio of 0.44, a quick ratio of 5.97 and a current ratio of 6.60. Basilea Pharmaceutica has a 12-month low of $59.29 and a 12-month high of $84.00.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.
Recommended Stories
- Five stocks we like better than Basilea Pharmaceutica
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
